Zenosense, Inc. (ZENO) Early Detection Technology Saves Live Zenosense, Inc. (ZENO) Early Detection Technology Saves Lives and Money
Infectious disease was the leading cause of death in the United States until the discovery of antibiotics to treat bacterial infections in 1920’s. Penicillin proved a powerful weapon to fight disease and was even effective in combating deadly staph infections. Staph is a common bacterium, found on the skin or in the nose of even healthy individuals but becomes serious if it invades deeper into the skin, blood or organs. The malevolent staph bacteria developed resistance to penicillin in the 1940’s and medical science was forced to find to another antibiotic, methicillin to treat staph. Even so, by the 1960s staph had become resistant to it too and the virulent strain of staph infection, MRSA (Methicillin-resistant Staphylococcus aureus) was upon us. Health care professionals have now been combating MRSA for over 50 years.
The Centers for Disease Control and Prevention (CDC) estimated 80,500 cases of invasive MRSA and 11,000 deaths in the US in 2011. However, the CDC tracks only invasive MRSA infections where the staph bacteria have reached the bloodstream or invaded internal organs. In same year there were nearly 460,000 hospitalizations involving a MRSA diagnosis and data suggests these hospitalizations resulted in over 20,000 deaths. The inability to detect or track MRSA cases is complicating efforts by public health officials to develop prevention strategies and keep the bacteria from threatening vast new segments of the population.
In addition to the serious individual and public health issues caused by MRSA, it also places a severe financial impact on private and public health care systems. Early detection is vital to effectuate protective measures for patients and stop the spread of the disease. Currently there is no cost effective system early detection system for MRSA in the patient or in the rooms of a healthcare building. Zenosense, Inc. is focused on developing this much needed MRSA early detection device.
The Zenosense, Inc. patent-pending device is being designed to sample air and continuously monitor for the airborne Volatile Organic Compounds (“VOCs”) signature emitted by MRSA. This cutting-edge detection device is intended to be produced as a low cost unit to be worn by patients and medical staff. In the event of any infection, the MRSA device will detect the VOCs produced by the infected person and emit an audio/visual alarm. There is also a network monitored hard wired detection device planned to be positioned in the room with a magnifier for MRSA presence. Zenosense has actively been developing these products since December 2013 for this multi-million dollar market. As Zenosense has moved forward in development they have put multiple strategic relationships in place with hospitals, universities, and the high tech private sector to facilitate both research and roll out.
These relationships have led the company into another lucrative untapped market. Zenosense believes a vast global opportunity exists for a low cost lung cancer detection device used at point of care. A device that matches or exceeds the accuracy of a Tomography scan would be in universal demand as a complimentary, indicative test to increase early detection and achieve best outcomes.
Once to market these early detection devices can easily save lives, save money for public and private health facilities and potentially deliver vast rewards for Zenosense investors.
For more information, visit: www.zenosense.net
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com